In some cancer cases, PD1/PDL1 antibody therapies invigorate tumor-infiltrating CD8+ T lymphocytes, but their efficacy on heterogeneous CD8+ T cell populations is uneven (193). The gene discussed is CD274; the disease is neoplasm.